RE:RE:RE:RE:We are waiting for an explanation RealstockyI wouldn’t disagree with you, Stockman. All the more incentive for LMNl to sell the Ryplazim platform upon approval along with the voucher if granted. A big dividend could be granted after sale, enabling all shareholders to get their money back plus a little profitwhile leaving $100-150M to further the small molecule opportunity. If Phase 2 placebo controlled trials of 4050are successful, I could see the small molecule division sold off to the highest bidder Shortly thereafter.
The fact that Culow has been replaced by the new President of Thomvest signals to me that Thomvest is interested in getting as much as possible from the Lmnl in the shortest timeframe possible. They are no longer interested in even developing each asset for 3-5 years to maximise return. I believe the new mantra is ‘get good results and get out!
The fact that Culow enabled the Fairhaven deal to go thru may have led to his ouster as such a move does not fit with the new philosophy. That’s what I think anyway.